Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure: Current Evidence and Future Opportunities.
Sho SuzukiTakeshi KitaiIoannis SkoularigisKyriakos SpiliopoulosAndrew V XanthopoulosPublished in: Journal of personalized medicine (2023)
Atrial fibrillation (AF) and heart failure (HF) are highly prevalent cardiac disorders worldwide, and both are associated with poor prognosis. The incidence of AF and HF has been increasing substantially in recent years, mainly due to the progressive aging of the population. These disorders often coexist, and may have a causal relationship, with one contributing to the development or progression of the other. AF is a significant risk factor for adverse outcomes in HF patients, including mortality, hospitalization, and stroke. Although the optimal treatment for AF with HF remains unclear, catheter ablation (CA) has emerged as a promising treatment option. This review provides a comprehensive overview of the current scientific evidence regarding the efficacy of CA for managing AF in HF patients. In addition, the potential benefits and risks associated with CA are also discussed. We will also explore the factors that may influence treatment outcomes and highlight the remaining gaps in knowledge in this field.
Keyphrases
- atrial fibrillation
- catheter ablation
- left atrial
- heart failure
- left atrial appendage
- oral anticoagulants
- direct oral anticoagulants
- poor prognosis
- end stage renal disease
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- long non coding rna
- multiple sclerosis
- left ventricular
- cardiovascular disease
- replacement therapy
- cardiac resynchronization therapy